Drug Details

General Information of the Drug (ID: DR0261)
Name
Zoledronic
Synonyms
Zoledronic acid; Zoledronate; 118072-93-8; Zometa; Reclast; Aclasta; (1-Hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl)diphosphonic acid; CGP 42446; (1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid; ZOL; CGP-42446; [1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid); Orazol; UNII-70HZ18PH24; (1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid; Phosphonic acid, [1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis-; C5H10N2O7P2; Reclast (TN); Zometa (TN); CHEMBL924; CHEBI:46557; [1-hydroxy-2-(1H-imidazol-1-yl)-1-phosphonoethyl]phosphonic acid; 70HZ18PH24; CGP-42446A; NCGC00159521-02; (1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid; Zoledronic acid [USAN:INN:BAN]; Phosphonic acid, (1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bis-; Zomera; 1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyldiphosphonic acid; Bisphosphonate 3; Zometa (Novartis); Aclasta and Reclast; AK-156; Zoledronic acid (INN); Zoledronic Acid Anhydrous; [1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene]bisphosphonic acid; zoledronic-acid; BPH 91; ZOL 446; PubChem14894; Anhydrous Zoledronic Acid; Zoledronic Acid, Anhydrous; DSSTox_CID_22668; DSSTox_RID_80065; Zoledronic acid, Zoledronate; BIDD:PXR0134; DSSTox_GSID_42668; SCHEMBL19054; BIDD:GT0292; Zoledronic Acid (Zoledronate); GTPL3177; JMC515594 Compound 55; PHO012; DTXSID0042668; BDBM12578; HMS2089O09; BCP22750; EBD33252; ZINC3803652; Tox21_111739; [1-HYDROXY-2-(1H-IMIDAZOL-1-YL)-ETHYLIDENE]BISPHOSPHONIC ACID; ANW-57498; MFCD00867791; NSC721517; s1314; STL452893; AKOS005145739; AB07564; AC-1092; CS-1829; DB00399; HS-0091; MCULE-1604726355; NSC 721517; NSC-721517; NCGC00159521-03; NCGC00159521-04; NCGC00159521-05; NCGC00159521-09; NCGC00159521-18; AK-81486; HY-13777; AB0013187; CAS-118072-93-8; FT-0601384; Y1607; D08689; S00092; Z-1463; 42181-EP2270008A1; 42181-EP2292617A1; 42181-EP2295426A1; 42181-EP2295427A1; 42181-EP2308855A1; 42181-EP2311808A1; 42181-EP2311829A1; AB01273947-01; AB01273947-02; AB01273947-03; AB01273947_04; 072Z938; Q218507; SR-05000001436; Q-201946; SR-05000001436-1; [1-hydroxy-(1H-imidazol-1-yl)-phosphonoethyl] phos; 1-Hydroxy-2-(1-imidazolyl)ethane-1,1-diphosphonic Acid; Z1691545083; Phosphonic acid, P,P'-[1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis-
    Click to Show/Hide
Molecular Type
Small molecule
Disease Mineral excesses [ICD-11: 5B91] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C5H10N2O7P2
PubChem CID
68740
Canonical SMILES
C1=CN(C=N1)CC(O)(P(=O)(O)O)P(=O)(O)O
InChI
1S/C5H10N2O7P2/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14)
InChIKey
XRASPMIURGNCCH-UHFFFAOYSA-N
CAS Number
CAS 118072-93-8
ChEBI ID
CHEBI:46557
TTD Drug ID
D0VM2L
DrugBank ID
DB00399
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Gossypol      Gossypium herbaceum     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Up-regulation Expression BAD  Molecule Info 
Pathway MAP
Up-regulation Expression BAX  Molecule Info 
Pathway MAP
Down-regulation Expression BIRC2  Molecule Info 
Pathway MAP
Down-regulation Expression BIRC3  Molecule Info 
Pathway MAP
Down-regulation Expression BIRC5  Molecule Info 
Pathway MAP
Up-regulation Cleavage CASP3  Molecule Info 
Pathway MAP
Up-regulation Expression CDKN1B  Molecule Info 
Pathway MAP
Down-regulation Expression CLSPN  Molecule Info 
Pathway MAP
Up-regulation Expression FAS  Molecule Info 
Pathway MAP
Down-regulation Expression HMOX1  Molecule Info 
Pathway MAP
Down-regulation Expression HSP20  Molecule Info 
Pathway MAP
Down-regulation Expression HSPD1  Molecule Info 
Pathway MAP
Down-regulation Expression ML-IAP  Molecule Info 
Pathway MAP
Down-regulation Expression PON2  Molecule Info 
Pathway MAP
Down-regulation Expression TP53  Molecule Info 
Pathway MAP
                    In-vitro Model DU145 CVCL_0105 Prostate carcinoma Homo sapiens
                    Experimental
                    Result(s)		 GP significantly enhances the anti-tumor activity of ZA in hormone- and drug-resistant prostate cancer cells by targeting many pivotal apoptosis-related proteins.
          Plumbagin      Plumbago europaea     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [3]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Down-regulation Expression BCL-2  Molecule Info 
Pathway MAP
Up-regulation Expression NOTCH1  Molecule Info 
Pathway MAP
                    In-vitro Model MDA-MB-231 CVCL_0062 Breast adenocarcinoma Homo sapiens
                    Experimental
                    Result(s)		 Combination of Zoledronic acid and Plumbagin synergistically suppresses human breast cancer MDA-MB-231SArfp cells in vitro. Plumbagin can inhibit Zoledronic acid-induced activation of the Notch-1 signaling pathway and subsequently reduce the expression of Bcl-2, thus potentiating cancer cell apoptosis.
          Thymoquinone      Nigella sativa     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [4]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Up-regulation Expression CASP3  Molecule Info 
Pathway MAP
Up-regulation Expression CASP7  Molecule Info 
Pathway MAP
                    Biological
                    Regulation		 Increase DNA fragmentation
                    In-vitro Model PC-3 CVCL_0035 Prostate carcinoma Homo sapiens
DU145 CVCL_0105 Prostate carcinoma Homo sapiens
                    Experimental
                    Result(s)		 The combination of TQ and ZA resulted in a significant synergistic cytotoxic activity and DNA fragmentation when compared to any single agent alone, in a dose- and time-dependent manner.
Target and Pathway
Target(s) Geranyltranstransferase (FDPS)  Molecule Info  [5]
BioCyc Superpathway of geranylgeranyldiphosphate biosynthesis I (via mevalonate) Click to Show/Hide
2 Superpathway of cholesterol biosynthesis
3 Trans, trans-farnesyl diphosphate biosynthesis
4 Geranylgeranyldiphosphate biosynthesis
KEGG Pathway Terpenoid backbone biosynthesis Click to Show/Hide
2 Metabolic pathways
3 Biosynthesis of antibiotics
4 Influenza A
5 HTLV-I infection
NetPath Pathway TCR Signaling Pathway Click to Show/Hide
Panther Pathway Cholesterol biosynthesis Click to Show/Hide
Pathwhiz Pathway Steroid Biosynthesis Click to Show/Hide
Reactome Cholesterol biosynthesis Click to Show/Hide
2 Activation of gene expression by SREBF (SREBP)
WikiPathways Activation of Gene Expression by SREBP (SREBF) Click to Show/Hide
2 SREBP signalling
3 Cholesterol Biosynthesis
References
Reference 1 Current and future treatments of bone metastases. Expert Opin Emerg Drugs. 2008 Dec;13(4):609-27.
Reference 2 Targeting apoptosis in the hormone- and drug-resistant prostate cancer cell line, DU-145, by gossypol/zoledronic acid combination. Cell Biol Int. 2009 Nov;33(11):1165-72.
Reference 3 Synergistic suppression of human breast cancer cells by combination of plumbagin and zoledronic acid In vitro. Acta Pharmacol Sin. 2015 Sep;36(9):1085-98.
Reference 4 Enhanced cytotoxicity and apoptosis by thymoquinone in combination with zoledronic acid in hormone- and drug-resistant prostate cancer cell lines. J BUON. Oct-Dec 2014;19(4):1055-61.
Reference 5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link